Dietrich Stephan leaving LifeX to join portfolio firm that’s merging with Ohr Pharmaceutical


LifeX Labs, a Pittsburgh-based startup incubator, announced Friday that its portfolio company created to address genetic diseases — NeuBase Therapeutics — will merge with New York-based Ohr Pharmaceuticals. Dr. Dietrich A. Stephan, who had served as CEO of LifeX, will lead the newly combined company.

NeuBase was created a little over a year ago to develop a modular peptide-nucleic acid antisense oligonucleotide platform to provide a single, cohesive approach toward genetic diseases caused by…

Previous Hospitals provide charges online, but it's not as useful as you might think
Next Denver housing market suffers drastic swing in 2018